Preclinical studies have shown that mTOR inhibitors like rapamycin can reduce polyp proliferation in APC mutant models, and early clinical evidence, including a small case series, suggested beneficial effects on polyp size and dysplasia in FAP patients. This evidence concerns the gene APC and Familial adenomatous polyposis.